LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "cd7" as a keyword



Photo by nci from unsplash

The clinical importance of CD4+CD7− in human diseases

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Cellular Physiology"

DOI: 10.1002/jcp.27099

Abstract: The CD7 antigen is a member of the immunoglobulin superfamily that expresses on the surface of all thymocytes, a majority of mature T cells, and also natural killer cells. Interestingly, under physiological and different pathological… read more here.

Keywords: clinical importance; cd4 cd7; importance cd4; cd7 ... See more keywords

A bispecific antibody–drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia

Sign Up to like & get
recommendations! Published in 2025 at "mAbs"

DOI: 10.1080/19420862.2025.2551205

Abstract: ABSTRACT Acute myeloid leukemia (AML) is a heterogeneous malignancy with poor clinical outcome. Aberrant expression of CD7 in AML patients is linked to shorter overall survival and lack of response to standard of care therapy.… read more here.

Keywords: cd7; acute myeloid; tumor; myeloid leukemia ... See more keywords
Photo from wikipedia

111 Highly efficient multiplexed base editing enables development of universal CD7-targeting CAR-T Cells to treat T-ALL

Sign Up to like & get
recommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"

DOI: 10.1136/jitc-2020-sitc2020.0111

Abstract: Background Autologous CAR-T therapies have demonstrated remarkable efficacy in treating some hematologic cancers. However, generating bespoke cell therapies creates manufacturing challenges, inconsistent products, high cost of goods, and delays in treatment that are often incompatible… read more here.

Keywords: base editing; allogeneic car; base; cd7 ... See more keywords

Engineering Naturally Occurring CD7 Negative Cells for the Immunotherapy of CD7 Positive Leukemia

Sign Up to like & get
recommendations! Published in 2019 at "Blood"

DOI: 10.1182/blood-2019-124903

Abstract: Background: CD7 has emerged as a promising target for the adoptive immunotherapy with T-cells expressing chimeric antigen receptors (CAR T-cells) of CD7+ T-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML). However, expressing CD7… read more here.

Keywords: cd7 carcd7; cd7 cells; carcd7 cells; cd7 ... See more keywords

CD7-Targeted CAR-T Cell Therapy Shows Promising Efficacy and Safety in Treating Refractory/Relapsed Peripheral T-Cell Lymphoma: Phase I Clinical Trial

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-196853

Abstract: Introduction Peripheral T-cell lymphomas (PTCL) encompass a broad class of heterogeneous clinicopathologic entities unified in their derivation from a mature, post-thymic T-cell. For patients with relapsed or refractory (R/R) PTCL, outcomes are generally poor, even… read more here.

Keywords: cd7; cell lymphoma; therapy; car ... See more keywords

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Sign Up to like & get
recommendations! Published in 2025 at "Blood"

DOI: 10.1182/blood-2025-1042

Abstract: Background R/R T-ALL/LBL poses significant therapeutic challenge due to paucity, and limited efficacy, of treatments. CTD402, is a CD7 targeted “off-the-shelf” universal CAR-T product with T cell receptor and human leukocyte antigen class II knockout,… read more here.

Keywords: cd7; post; ctd402; car ... See more keywords

Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL/LBL: First-in-human Phase I Clinical Trial.

Sign Up to like & get
recommendations! Published in 2022 at "Blood"

DOI: 10.1182/blood.2021014498

Abstract: Derivation of CD7-targeted chimeric antigen receptor (7CAR) T cells often requires genetic manipulations to ablate the CD7 gene or block CD7 cell surface expression. Our novel approach deriving naturally selected 7CAR-T cells (NS7CAR) from bulk… read more here.

Keywords: 7car cells; genetic manipulations; cd7; trial ... See more keywords

Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia.

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood.2024024861

Abstract: Approximately 30% of acute myeloid leukemia (AML) patients express CD7 on their myeloblasts. We have previously demonstrated that scFv-based "naturally selected" CD7 CAR-T (NS7CAR-T) therapy shows significant efficacy with a favorable safety profile in T-cell… read more here.

Keywords: cd7; acute myeloid; ns7car; naturally selected ... See more keywords

Chimeric Antigen Receptor (CAR) T Cell Therapy for CD7-Positive Acute Myeloid Leukemia

Sign Up to like & get
recommendations! Published in 2017 at "Blood"

DOI: 10.1182/blood.v130.suppl_1.2642.2642

Abstract: Expression of CD7 is an adverse prognostic factor in both AML and myelodysplastic syndromes. Because CD7 is not constitutively expressed by mature myeloid cells or early myeloid progenitor cells, we explored the feasibility of targeting… read more here.

Keywords: cd7; car7 cells; aml; research funding ... See more keywords
Photo by lkxznup from unsplash

Intracellular retention of TCRαβ/CD3 and CD7 to generate novel allogeneic CAR-T cells targeting CD7 for treating T-cell malignancies.

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2024.42.16_suppl.e14531

Abstract: e14531 Background: The treatment for patients with T-ALL/LBL who relapse after hematopoietic stem cell transplantation (HSCT) are currently restricted. CD7 is highly expressed on the surface of T-ALL/LBL T cells and CAR-T cell therapy provides… read more here.

Keywords: cd7; cd3; car; cell ... See more keywords

Association of enrichment of CD7⁺CXCR3⁺ CAR T cells in infusion products with remission in relapsed or refractory diffuse large B-cell lymphoma.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2025.43.16_suppl.7020

Abstract: 7020 Background: Chimeric antigen receptor (CAR) T-cell therapy is the standard of care for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), yet more than half of patients do not achieve durable remission. Identifying… read more here.

Keywords: cd7; cxcr3; car cell; car ... See more keywords